Smith+Nephew to Showcase Growth-Driving Surgical Innovations at June Investor Event
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Smith & Nephew Snats ( (SNN) ).
Smith+Nephew, the London-listed medical technology group, will host an expert surgeon insights event for investors and analysts in London on 9 June 2026, the company said on 27 April 2026. The half‑day session will showcase innovation platforms underpinning its RISE strategy, including the REGENETEN and CARTIHEAL implants, the TESSA Spatial Surgery System, the PICO single‑use negative pressure wound therapy system, and the CORI, AETOS and new LANDMARK orthopaedic systems.
Chief executive Deepak Nath and chief financial officer John Rogers, joined by executive committee members, will lead the event, which will feature product demonstrations and Q&A with both surgeons and management. Presentations from leading US surgeons will highlight trends such as the shift of joint replacement to ambulatory surgery centres, growing use of robotics and spatial surgery, and efforts to reduce surgical site complications, underscoring Smith+Nephew’s push to position its portfolio at the forefront of orthopaedics and sports medicine practice.
The most recent analyst rating on (SNN) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith+Nephew is a global medical technology company focused on the repair, regeneration and replacement of soft and hard tissue across Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. Founded in Hull, UK, in 1856, it now operates in around 100 countries, generated $6.2 billion in sales in 2025, employs about 17,000 people and is a constituent of the FTSE 100 index.
Average Trading Volume: 884,639
Technical Sentiment Signal: Buy
Current Market Cap: $13.37B
Find detailed analytics on SNN stock on TipRanks’ Stock Analysis page.
